Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ: TARS · Real-Time Price · USD
40.88
-0.07 (-0.17%)
At close: Jun 13, 2025, 4:00 PM
40.89
+0.01 (0.02%)
After-hours: Jun 13, 2025, 4:00 PM EDT
Tarsus Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Tarsus Pharmaceuticals stock ranges from a low of $51 to a high of $84. The average analyst price target of $67.14 forecasts a 64.24% increase in the stock price over the next year.
Price Target: $67.14 (+64.24%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tarsus Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 4 | 4 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +76.13% | May 27, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $46 → $51 | Hold | Maintains | $46 → $51 | +24.76% | May 5, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $78 → $84 | Strong Buy | Maintains | $78 → $84 | +105.48% | May 2, 2025 |
Jefferies | Jefferies | Strong Buy Maintains $54 → $58 | Strong Buy | Maintains | $54 → $58 | +41.88% | Mar 6, 2025 |
Guggenheim | Guggenheim | Strong Buy Maintains $75 → $78 | Strong Buy | Maintains | $75 → $78 | +90.80% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
407.88M
from 182.95M
Increased by 122.94%
Revenue Next Year
587.91M
from 407.88M
Increased by 44.14%
EPS This Year
-1.24
from -3.07
EPS Next Year
1.86
from -1.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 452.2M | 747.0M | 940.9M | ||
Avg | 407.9M | 587.9M | 806.4M | ||
Low | 352.1M | 416.4M | 658.0M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 147.2% | 83.1% | 60.0% | ||
Avg | 122.9% | 44.1% | 37.2% | ||
Low | 92.4% | 2.1% | 11.9% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.69 | 3.54 | 8.10 | ||
Avg | -1.24 | 1.86 | 5.09 | ||
Low | -1.62 | 1.13 | 3.25 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 335.3% | ||
Avg | - | - | 173.5% | ||
Low | - | - | 74.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.